WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent upon the achievement of specified financial milestones to be determined at a future date, which could include revenue and earnings targets. Any consideration of a special dividend would be subject to the Company’s future fin ...

Core Viewpoint - Tevogen Bio Holdings Inc. has made a significant charitable contribution of 230,000 shares to support underserved communities through a recognized nonprofit organization [2][3] Company Overview - Tevogen is a next-generation healthcare enterprise focused on affordability, efficiency, and scientific rigor, utilizing AI and precision T cell therapy platforms [4] - The company aims to develop advanced therapies across various therapeutic areas and enhance the healthcare system's scalability [4] Clinical Development - Tevogen Bio has completed a proof-of-concept clinical trial for its genetically unmodified allogeneic T cells, indicating potential in treating various diseases [5] - The pipeline includes programs in virology, oncology, and neurology, leveraging the proprietary ExacTcell™ platform [5] Technological Innovation - Tevogen.AI is designed to enhance drug development by improving target detection and clinical trial design through predictive technologies [6] - The platform collaborates with major technology providers like Microsoft and Databricks to facilitate rapid therapeutic discovery [6] Strategic Initiatives - The company is exploring future initiatives in domestic generics, biosimilars, medical devices, and innovative insurance solutions to broaden patient access [7] - These initiatives align with Tevogen's mission to promote sustainable innovation and create a more equitable healthcare model [7]

Core Viewpoint - Tevogen Bio Holdings Inc. demonstrates its commitment to community support through a significant donation of 50,000 shares by its Founder and CEO, Dr. Ryan Saadi, to the Mt. Bethel Fire Company, reflecting the company's dedication to local first responders and the Warren Township community [2][3][4]. Company Overview - Tevogen is a next-generation healthcare enterprise focused on affordability, efficiency, and scientific rigor, utilizing advanced artificial intelligence and precision T cell therapy platforms to develop life-saving therapies [5]. - The company has an estimated asset valuation of $10 billion and a secured cash runway for commercialization, indicating strong financial health and growth potential [4]. Clinical and Technological Advancements - Tevogen Bio has completed a proof-of-concept clinical trial for its single-HLA–restricted, genetically unmodified allogeneic T cells, with a pipeline that includes programs in virology, oncology, and neurology [6]. - The Tevogen.AI platform aims to transform drug development by enhancing target detection and optimizing clinical trial design, utilizing cloud and data services from major technology providers [7][8]. Strategic Initiatives - Tevogen is exploring future initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions, reflecting its mission to advance sustainable innovation and broaden patient access [9].

Core Viewpoint - Tevogen Bio Holdings Inc. has made a significant contribution to the Warren Township Honorary Policemen's Benevolent Association, with its Founder and CEO, Dr. Ryan Saadi, donating 230,000 shares of common stock to support local community initiatives [2][3][4]. Group 1: Donation Impact - The donation will be utilized to acquire critical equipment that enhances the safety of police officers and residents, thereby strengthening community services [6][7]. - The contribution reflects a commitment to community welfare and acknowledges the importance of law enforcement in maintaining safety [5][8]. Group 2: Company Overview - Tevogen is recognized for its disciplined execution and has a significant multi-billion-dollar potential in its long-term vision, emphasizing responsibility towards the communities it serves [9]. - The company operates as a next-generation healthcare enterprise, focusing on affordability, efficiency, and scientific rigor, leveraging advanced technologies for developing life-saving therapies [11]. Group 3: Research and Development - Tevogen Bio has completed a proof-of-concept clinical trial for its T cell therapy, with a pipeline that spans virology, oncology, and neurology [12]. - The company is also developing Tevogen.AI, a platform aimed at transforming drug development through advanced predictive technologies [13]. Group 4: Future Initiatives - Tevogen is exploring strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions, reflecting its mission to advance sustainable innovation in healthcare [14].

Core Points - Tevogen Bio Holdings Inc. announced a significant donation of 230,000 shares from its Founder and CEO, Dr. Ryan Saadi, to the Warren Township Honorary Policemen's Benevolent Association [2][10] - The donation aims to support local community initiatives, including safety equipment for police officers and community welfare programs [3][6] Company Overview - Tevogen is a next-generation healthcare enterprise focused on affordability, efficiency, and scientific rigor, utilizing advanced technologies for developing life-saving therapies [11] - The company has a diverse pipeline that includes programs in virology, oncology, and neurology, leveraging its proprietary ExacTcell™ platform [12] Community Engagement - The donation reflects Tevogen's commitment to community responsibility and enhancing the safety of local law enforcement [9][8] - The funds will be allocated for critical equipment to improve the safety and effectiveness of police services in Warren Township [6][7]

Core Insights - Tevogen Bio Holdings Inc. recognizes Dr. Curtis Patton for his significant contributions to the field of medicine and the company, particularly in advancing its ExacTcell™ precision T cell platform and achieving revenue forecasts exceeding $1 billion [3][4]. Company Overview - Tevogen is a next-generation healthcare enterprise focused on affordability, efficiency, and scientific rigor, leveraging AI and precision T cell therapy platforms to develop life-saving therapies [6]. - The company has completed a proof-of-concept clinical trial for its allogeneic T cells, with a pipeline that includes programs in virology, oncology, and neurology [7]. Technological Advancements - Tevogen.AI aims to transform drug development by enhancing target detection and optimizing clinical trial design through proprietary predictive technologies, utilizing cloud services from major tech providers [8]. Strategic Initiatives - The company is exploring future initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions, reflecting its mission to advance sustainable innovation and broaden patient access [9].

Core Insights - Tevogen Bio is experiencing significant public interest in its investigational precision T cell therapy, TVGN 489, which is being developed for COVID-19 and Long COVID [1][2] - The CEO of Tevogen Bio highlighted the urgent need for effective solutions for Long COVID patients, emphasizing the company's commitment to advancing its research [2] - The clinical trial for TVGN 489 has shown a favorable safety profile and has provided insights for further development, with results published in a peer-reviewed journal [2] Development Plans - Tevogen is preparing for the next stage of development for TVGN 489 and plans to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite the process [3][7] - The company has established a dedicated communication channel for Long COVID updates to manage the high volume of patient inquiries [4][7] Financial Strategy - Tevogen is focused on maximizing capital efficiency and maintaining access to financing to support its growth and commercialization efforts [4]